The Max Delbrück Center for Molecular Medicine in the Helmholtz Association aims to transform tomorrow’s medicine through our discoveries of today. At locations in Berlin-Buch, Berlin-Mitte, Heidelberg and Mannheim, our scientists collaborate across disciplines to unravel the complexities of disease at the systems level – from molecules and cells to organs and entire organisms. Through strong academic, clinical, and industry partnerships, as well as global networks, we translate biological insights into innovations for early detection, individualized therapies, and disease prevention. Founded in 1992, the Max Delbrück Center is home to a vibrant community of 1,800 people from more than 70 countries.
Our diverse workforce is a core strength that inspires creativity and innovation at the Max Delbrück Center (MDC).
The MDC is committed to improving human health through transformative biomedical research. Our goal is to pioneer discoveries for preventing, treating, and ultimately curing disease. The Daumke Group at the MDC combines structural biology, biochemical and cell biological methods to understand the molecular mechanisms of membrane trafficking. In the current project, we seek to develop novel protein therapeutics targeting cancer-related signaling pathways.
The current position is a part of the Helmholtz Bioengineering Consortium, including generative AI experts, structural and molecular biologists and clinicians to develop anticancer therapeutics by protein design.
MNCJobs.de will not be responsible for any payment made to a third-party. All Terms of Use are applicable.